It is a good question bigcheese and one I often ask myself. I...

It is a good question bigcheese and one I often ask myself.

I was in SPL when it was a pooled investment many years ago before selling out due to delays. Was out for years before I started to buy back in from late 16 onwards and will now hold for the Long term, too many near term milestones. The recent quarterly outlook below is pretty clear on the opportunities. Aspen launch, global / regional deals and the dep doc trials are what I am most eagerly awaiting. If Dep doc goes as planned it will be beyond huge.

Now is the time to be patient in my humble view.

Outlook
 Aspen’s launch of VivaGel® BV as Fleurstat BV gel in Australia
 Execution of multiple licences for VivaGel® BV (multiple territories/licences)
 FDA approval of NDA for VivaGel® BV
 Further regulatory approvals and launch of VivaGel® BV in other regions
 Advancement of the AstraZeneca DEP® programs, including AZD0466 and associated milestone payments
 Progress with the phase 2 DEP® docetaxel clinical trial and phase 1/2 DEP® cabazitaxel clinical trial, and further site(s) commencing recruitment
 Progress with other DEP® internal candidates, including DEP® irinotecan, and other partnered DEP® programs
 Other partnered DEP® deals anticipated
 Further regulatory approvals and launch of the VivaGel® condom in other regions